Veradermics, Incorporated (MANE), a late clinical-stage biopharmaceutical company, announced the pricing of its upsized initial public offering of 15.08 million shares at $17 per share.
In addition, Veradermics has granted the underwriters a 30-day option to purchase up to an additional 2.26 million shares.
Gross proceeds from the offering, which is expected to close on February 5, are estimated to be approximately $256.3 million.
Veradermics' stock is expected to begin trading on the New York Stock Exchange on February 4, under the ticker symbol MANE.
Jefferies, Leerink Partners, Citigroup, and Cantor are acting as joint book-running managers for the offering.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.